

Receipt date: 10/18/2005

10/1553434 AU: 1614

JC06 Rec'd PCT/PTO 18 OCT 2009

Page 1 of 1

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1089.0580000/MAC/SJE	APPLICATION NO. To be assigned (U.S. National Phase of PCT/JP2004/006038; Int'l Filing Date: April 23, 2004)
		FIRST NAMED INVENTOR Iwata OZAKI	
		FILING DATE 10/18/05	ART UNIT 1614 To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	JP 6-305955 A	11/01/1994	Japan			X Yes No
	AM1	JP 2004-067513 A	03/04/2004	Japan			X Yes No
	AN1	JP 2004-107330 A	04/08/2004	Japan			X Yes No
	AO1	WO 2004/056351 A1	07/08/2004	WIPO			Yes X No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		
AS		
AT		

EXAMINER /Leslie A. Royds/ (06/04/2009)	DATE CONSIDERED
--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

10/553434 43AU: 1614
JC06 Rec'd PCT/PTO 18 OCT 2005

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	To be assigned (U.S. National Phase of PCT/JP2004/006038; Int'l Filing Date: April 23, 2004)
				Filing Date	Herewith 10/18/05
				First Named Inventor	Iwata OZAKI
				Art Unit	To be assigned 1614
				Examiner Name	To be assigned L. Royds
Sheet	1	of	1	Attorney Docket Number	1089.0580000/MAC/SJE

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	International Search Report for International Application No. PCT/JP2004/006038, Japanese Patent Office, mailed August 12, 2004	
	NPL2	MIYAZAWA, K., et al., "Combined treatment of leukemia cells with l-alpha, 25-dihydroxy-22-oxavitamin D3 plus vitamin K2 (VK2), results in synergistic enhancement of monocytic differentiation but also inhibition of VK2-inducing apoptosis by cytoplasmic p21CIP1," <i>Blood</i> 98 (11, pt 1): 353a, Presented at the 43rd Annual Meeting of the American Society of Hematology, Part I, Orlando, FL, American Society of Hematology (2001); printed from <i>Biol. Abstracts Inc.</i> , Accession No. 2002:186629	
	NPL3	NISHIKAWA, Y., et al., "Growth Inhibition of Hepatoma Cells Induced by Vitamin K and Its Analogs," <i>J. Biol. Chem.</i> 270:28304-28310, The American Society for Biochemistry and Molecular Biology, Inc. (1995)	
	NPL4	OKAYASU, H., et al., "Cytotoxic Activity of Vitamins K ₁ , K ₂ and K ₃ against Human Oral Tumor Cell Lines," <i>Anticancer Research</i> 21:2387-2392, J.G. Delinassios (2001)	
	NPL5	OTSUKA, M., et al., "Inhibition of Hepatoma Cell Growth and Invasion by Vitamin K2 Administration In Vitro," Presented at the 53rd Annual Meeting on the Liver, Boston, MA, <i>Hepatology</i> 36:445A, Abstract 1130, W.B. Saunders (October, 2002)	
	NPL6	MIYAGAWA, T., et al., "Vitamin K no Kogan Sayo," <i>Vitamin</i> 74:74-76, Kyoto Nippon Bitamin Gakkai (2000)	X
	NPL7	MIZUTA, T., et al., "Vitamin K ni yoru Kansaibo Gan Saihatsu Yokusei Koka no Rinshoteki Kento," <i>Japanese Journal of Gastroenterology</i> 99 Suppl.:A192, Abstract No. 308, Rinji Zokango (Sokai) (March, 2002)	X
	NPL8	MIZUTA, T., et al., "Vitamin K Toyo ni yoru Kansaibo Gan Saihatsu Yokusei Koka no Kento (Inhibitory effect against the recurrence of hepatocellular carcinoma by vitamin K administration)," Presented at <i>Dai 38 Kai Nihon Kangan Kenkyukai Syorokushu</i> (38th Annual Meeting of Liver Cancer Study Group Japan), p. 135, Abstract 110, (May 2002)	X
	NPL9	KOIKE, Y., et al., "Monmyakunai Shuyo Shinjun (PVI) Yobo o Mokuteki to shita Vitamin KII Toyo ni yoru Randomized Prospective Controlled Study", <i>Acta Hepatologica Japonica</i> 43(Suppl. 1):A64, Abstract O-98, Nihon Kanzo Gakkai (2002)	X
	NPL10	WU, F.Y.-H., et al., "Comparison of Antitumor Activity of Vitamins K1, K2, and K3 on Human Tumor Cells by Two (MTT and SRB) Cell Viability Assays," <i>Life Sciences</i> 52:1797-1804, Pergamon Press, Ltd. (1993)	

445582_1.DOC

Examiner Signature	/Leslie A. Royds/ (06/04/2009)	Date Considered	
--------------------	--------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (06/04/2009)